COM-2018-006

Recall: Acne Foam Recall Over Superpotency

At PharmPix we are committed to the health and well-being of patients. It is for this reason that we inform that on April 11, 2018 the FDA issued a statement notifying voluntary retirement of more than 3000 cans of Fabior (tazarotene) Foam, 0.1% manufactured by Mayne Pharma. The recall was made due to superpotency concerns. The recall affects 100-grams cans and the FDA designated it a Class III recall. . The affected lot is detailed in Table 1.

Table 1. Affected lot Fabior (tazarotene) Foam, 0.1%

Product	Affected Lot	Expiration date	NDC
Fabior (tazarotene) Foam, 0.1%	MBEB	01/31/2019	51862-295-10

The Pharmacy must:

1. Identify if they have the product in inventory and immediately stop using and dispensing the product.
2. It is important that pharmacy contact all members that in the previous 90 days received the recalled medication.
3. For questions regarding this recall can contact Mayne Pharma.

For additional information visit:

https://www.managedhealthcareconnect.com/content/acne-foam-recalled-over-superpotency

Department of Clinical Pharmacy